tanshinone has been researched along with Fatty Liver, Nonalcoholic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, Z; Fang, Z; Hong, Z; Hou, X; Liu, H; Liu, T; Luo, W; Mu, W; Ren, L; Shi, W; Wei, Z; Wen, J; Xiao, X; Xu, G; Yang, Y; Zhan, X; Zhao, J; Zou, W | 1 |
| Hu, R; Wang, J; Xiao, Y; Yin, C | 1 |
| Chen, HH; Chen, W; Ding, W; He, JM; Huang, L; Lu, TN; Wang, MQ; Wang, ZG; Yang, Q | 1 |
3 other study(ies) available for tanshinone and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Tanshinone I specifically suppresses NLRP3 inflammasome activation by disrupting the association of NLRP3 and ASC.
Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Disease Models, Animal; Inflammasomes; Interleukin-1beta; Lipopolysaccharides; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Non-alcoholic Fatty Liver Disease; Shock, Septic | 2023 |
Tanshinone IIA reduces palmitate-induced apoptosis via inhibition of endoplasmic reticulum stress in HepG2 liver cells.
Topics: Abietanes; Apoptosis; Caspase 3; Cell Survival; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Fatty Liver; Hep G2 Cells; Humans; Liver; Non-alcoholic Fatty Liver Disease; Palmitates | 2020 |
Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4.
Topics: Abietanes; Animals; Body Weight; Lipids; Liver; Male; Malondialdehyde; NF-kappa B; Non-alcoholic Fatty Liver Disease; Organ Size; Oxidation-Reduction; PPAR gamma; Rats, Sprague-Dawley; RNA, Messenger; Toll-Like Receptor 4 | 2019 |